Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus carboplatin and etoposide in previously untreated transformed small cell lung cancer
2025-524686-24-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of PF-08634404 in small cell lung cancer (SCLC), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate and Adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-524686-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524686-24-00.